BioNTech Gains 10% After Its COVID-19 Vaccine Gets Full Approval From FDA

Shares of BioNTech SE (BNTX) are currently gaining nearly 10% on Monday morning after the U.S. Food and Drug Administration gave full approval to Pfizer/BioNTech's COVID-19 vaccine for people age 16 and older. This is the first Covid vaccine to be fully approved by the drug regulator.

BNTX is currently trading at $381.75, up $33.07 or 9.48%, on the Nasdaq, on a volume of 4.4 million shares, above the average volume of 3.9 million shares. In the 52-week period, the stock has traded between $54.10 and $464.00. The stock has surged over 400% in that time frame.

The Pfizer/BioNTech vaccine, marketed as Comirnaty, has been authorized for emergency use in the US since last December for people age 16 and older. In May, the authorization was extended to those 12 and older.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT